-
公开(公告)号：US08859526B2
公开(公告)日：2014-10-14
申请号：US12893798
申请日：2010-09-29
Applicant: Kirk W. Johnson
Inventor： Kirk W. Johnson
IPC: A61K31/727 , A01N43/04 , A61K31/715 , A61K31/70 , A61K38/37 , C07K14/755 , A61K38/43 , A61K38/57 , C07K14/745 , A61K38/48 , A61K31/737 , A61K31/731 , A61K38/36 , A61K45/06
CPC classification number: A61K31/727 , A61K31/731 , A61K31/737 , A61K38/36 , A61K38/37 , A61K38/4846 , A61K45/06 , Y10S514/834 , A61K2300/00
Abstract: Methods for treating bleeding disorders using non-anticoagulant sulfated polysaccharides (NASPs) as procoagulants are disclosed. NASPs can be administered as single agents, or in combination with one another, or with other medications (such as factors VII, VIII and IX) to promote hemostasis. In particular, the use of NASPs in treatment of bleeding disorders, including congenital coagulation disorders, acquired coagulation disorders, and trauma induced hemorrhagic conditions is described.
Abstract translation: 公开了使用非抗凝血硫酸多糖（NASP）作为促凝剂治疗出血性疾病的方法。 NASP可以作为单一药剂或彼此组合施用，或与其它药物（例如因子VII，VIII和IX）一起施用以促进止血。 特别地，描述了使用NASP治疗出血性疾病，包括先天性凝血障碍，获得性凝血障碍和创伤诱导的出血性病症。
-
公开(公告)号：US08771973B2
公开(公告)日：2014-07-08
申请号：US13111746
申请日：2011-05-19
Applicant: Kirk W. Johnson
Inventor： Kirk W. Johnson
IPC: C12Q1/56
CPC classification number: A61K31/727 , A61K31/731 , A61K31/737 , A61K38/36 , A61K38/37 , A61K38/4846 , A61K45/06 , Y10S514/834 , A61K2300/00
Abstract: Methods for treating bleeding disorders using non-anticoagulant sulfated polysaccharides (NASPs) as procoagulants are disclosed. NASPs can be administered as single agents, or in combination with one another, or, with other medications (such as factors VII, VIII and IX) to promote hemostasis. In particular, the use of NASPs in treatment of bleeding disorders, including congenital coagulation disorders, acquired coagulation disorders, and trauma induced hemorrhagic conditions is described.
Abstract translation: 公开了使用非抗凝血硫酸多糖（NASP）作为促凝剂治疗出血性疾病的方法。 NASP可作为单一药物或彼此组合施用，或与其它药物（如因子VII，VIII和IX）一起施用以促进止血。 特别地，描述了使用NASP治疗出血性疾病，包括先天性凝血障碍，获得性凝血障碍和创伤诱导的出血性病症。
-
公开(公告)号：US20130184216A1
公开(公告)日：2013-07-18
申请号：US13760900
申请日：2013-02-06
Applicant: Baxter International Inc. , University of Connecticut
Inventor： Marc Besman , Erik Bjornson , Feroz Jameel , Ramesh Kashi , Michael Pikal , Serguei Tchessalov , John Carpenter
IPC: A61K38/37
CPC classification number: A61K38/37 , A61K9/0019 , A61K9/19 , A61K47/02 , A61K47/10 , A61K47/18 , A61K47/183 , A61K47/26 , A61K47/38 , Y10S514/834 , Y10S530/829
Abstract: A Factor VIII composition formulated without albumin, comprising the following formulation excipients in addition to Factor VIII: 4% to 10% of a bulking agent selected from the group consisting of mannitol, glycine and alanine; 1% to 4% of a stabilizing agent selected from the group consisting of sucrose, trehalose, raffinose, and arginine; 1 mM to 5 mM calcium salt; 100 mM to 300 mM NaCl; and a buffering agent for maintaining a pH of approximately between 6 and 8. Alternatively, the formulation can comprise 2% to 6% hydroxyethyl starch; 1% to 4% of a stabilizing agent selected from the group consisting of sucrose, trehalose, raffinose, and arginine; 1 mM to 5 mM calcium salt; 100 mM to 300 mM NaCl; and a buffering agent for maintaining a pH of approximately between 6 and 8. In a further embodiment, the formulation can comprise: 300 mM to 500 mM NaCl; 1% to 4% of a stabilizing agent selected from the group consisting of sucrose, trehalose, raffinose, and arginine; 1 mM to 5 mM calcium salt; and a buffering agent.
-
公开(公告)号：US20110237512A1
公开(公告)日：2011-09-29
申请号：US12893798
申请日：2010-09-29
Applicant: Kirk W. Johnson
Inventor： Kirk W. Johnson
IPC: A61K38/37 , A61K31/737 , A61K38/36 , A61P7/04
CPC classification number: A61K31/727 , A61K31/731 , A61K31/737 , A61K38/36 , A61K38/37 , A61K38/4846 , A61K45/06 , Y10S514/834 , A61K2300/00
Abstract: Methods for treating bleeding disorders using non-anticoagulant sulfated polysaccharides (NASPs) as procoagulants are disclosed. NASPs can be administered as single agents, or in combination with one another, or with other medications (such as factors VII, VIII and IX) to promote hemostasis. In particular, the use of NASPs in treatment of bleeding disorders, including congenital coagulation disorders, acquired coagulation disorders, and trauma induced hemorrhagic conditions is described.
Abstract translation: 公开了使用非抗凝血硫酸多糖（NASP）作为促凝剂治疗出血性疾病的方法。 NASP可以作为单一药剂或彼此组合施用，或与其它药物（例如因子VII，VIII和IX）一起施用以促进止血。 特别地，描述了使用NASP治疗出血性疾病，包括先天性凝血障碍，获得性凝血障碍和创伤诱导的出血性病症。
-
公开(公告)号：US20090281022A1
公开(公告)日：2009-11-12
申请号：US12503498
申请日：2009-07-15
Applicant: HANS KURT PINGEL , Niels Kristian Klausen
Inventor： HANS KURT PINGEL , Niels Kristian Klausen
IPC: A61K38/36 , C12P21/02 , C07K14/745
CPC classification number: C12N9/6437 , A61K38/00 , A61K38/4846 , C12P21/02 , C12Y304/21021 , G01N2400/02 , Y10S514/802 , Y10S514/834
Abstract: The present invention provides preparations of Factor VIIa polypeptides or Factor VIIa-related polypeptides that exhibit predetermined glycoform patterns. The preparations of the invention exhibit improved functional properties and are useful for treating Factor VII-mediated conditions.
Abstract translation: 本发明提供了表现出预定的糖型图案的因子VIIa多肽或因子VIIa相关多肽的制剂。 本发明的制剂表现出改善的功能性质，并且可用于治疗因子VII介导的病症。
-
公开(公告)号：US20080176791A1
公开(公告)日：2008-07-24
申请号：US11764770
申请日：2007-06-18
Applicant: Marc Besman , Erik Bjornson , Feroz Jameel , Ramesh Kashi , Michael Pikal , Serguei Tchessalov , John Carpenter
Inventor： Marc Besman , Erik Bjornson , Feroz Jameel , Ramesh Kashi , Michael Pikal , Serguei Tchessalov , John Carpenter
IPC: A61K38/37
CPC classification number: A61K38/37 , A61K9/0019 , A61K9/19 , A61K47/02 , A61K47/10 , A61K47/18 , A61K47/183 , A61K47/26 , A61K47/38 , Y10S514/834 , Y10S530/829
Abstract: A Factor VIII composition formulated without albumin, comprising the following formulation excipients in addition to Factor VIII: 4% to 10% of a bulking agent selected from the group consisting of mannitol, glycine and alanine; 1% to 4% of a stabilizing agent selected from the group consisting of sucrose, trehalose, raffinose, and arginine; 1 mM to 5 mM calcium salt; 100 mM to 300 mM NaCl; and a buffering agent for maintaining a pH of approximately between 6 and 8. Alternatively, the formulation can comprise 2% to 6% hydroxyethyl starch; 1% to 4% of a stabilizing agent selected from the group consisting of sucrose, trehalose, raffinose, and arginine; 1 mM to 5 mM calcium salt; 100 mM to 300 mM NaCl; and a buffering agent for maintaining a pH of approximately between 6 and 8. In a further embodiment, the formulation can comprise: 300 mM to 500 mM NaCl; 1% to 4% of a stabilizing agent selected from the group consisting of sucrose, trehalose, raffinose, and arginine; 1 mM to 5 mM calcium salt; and a buffering agent.
Abstract translation: 不含白蛋白的因子VIII组合物，除了因子VIII外还包含以下制剂赋形剂：4％至10％的选自甘露醇，甘氨酸和丙氨酸的填充剂; 1％至4％的选自蔗糖，海藻糖，棉子糖和精氨酸的稳定剂; 1mM至5mM钙盐; 100mM至300mM NaCl; 以及用于保持约6至8的pH的缓冲剂。或者，制剂可以包含2％至6％的羟乙基淀粉; 1％至4％的选自蔗糖，海藻糖，棉子糖和精氨酸的稳定剂; 1mM至5mM钙盐; 100mM至300mM NaCl; 以及用于保持约6至8的pH的缓冲剂。在另一个实施方案中，制剂可以包含：300mM至500mM NaCl; 1％至4％的选自蔗糖，海藻糖，棉子糖和精氨酸的稳定剂; 1mM至5mM钙盐; 和缓冲剂。
-
公开(公告)号：US07247707B2
公开(公告)日：2007-07-24
申请号：US11434634
申请日：2006-05-15
Applicant: Marc Besman , Erik Bjornson , Feroz Jameel , Ramesh Kashi , Michael Pikal , Serguei Tchessalov , John Carpenter
Inventor： Marc Besman , Erik Bjornson , Feroz Jameel , Ramesh Kashi , Michael Pikal , Serguei Tchessalov , John Carpenter
CPC classification number: A61K38/37 , A61K9/0019 , A61K9/19 , A61K47/02 , A61K47/10 , A61K47/18 , A61K47/183 , A61K47/26 , A61K47/38 , Y10S514/834 , Y10S530/829
Abstract: A Factor VIII composition formulated without albumin, comprising the following formulation excipients in addition to Factor VIII: 4% to 10% of a bulking agent selected from the group consisting of mannitol, glycine and alanine; 1% to 4% of a stabilizing agent selected from the group consisting of sucrose, trehalose, raffinose, and arginine; 1 mM to 5 mM calcium salt; 100 mM to 300 mM NaCl; and a buffering agent for maintaining a pH of approximately between 6 and 8. Alternatively, the formulation can comprise 2% to 6% hydroxyethyl starch; 1% to 4% of a stabilizing agent selected from the group consisting of sucrose, trehalose, raffinose, and arginine; 1 mM to 5 mM calcium salt; 100 mM to 300 mM NaCl; and a buffering agent for maintaining a pH of approximately between 6 and 8. In a further embodiment, the formulation can comprise: 300 mM to 500 mM NaCl; 1% to 4% of a stabilizing agent selected from the group consisting of sucrose, trehalose, raffinose, and arginine; 1 mM to 5 mM calcium salt; and a buffering agent.
Abstract translation: 不含白蛋白的因子VIII组合物，除了因子VIII外还包含以下制剂赋形剂：4％至10％的选自甘露醇，甘氨酸和丙氨酸的填充剂; 1％至4％的选自蔗糖，海藻糖，棉子糖和精氨酸的稳定剂; 1mM至5mM钙盐; 100mM至300mM NaCl; 以及用于保持约6至8的pH的缓冲剂。或者，制剂可以包含2％至6％的羟乙基淀粉; 1％至4％的选自蔗糖，海藻糖，棉子糖和精氨酸的稳定剂; 1mM至5mM钙盐; 100mM至300mM NaCl; 以及用于保持约6至8的pH的缓冲剂。在另一个实施方案中，制剂可以包含：300mM至500mM NaCl; 1％至4％的选自蔗糖，海藻糖，棉子糖和精氨酸的稳定剂; 1mM至5mM钙盐; 和缓冲剂。
-
公开(公告)号：US07101557B2
公开(公告)日：2006-09-05
申请号：US10375741
申请日：2003-02-27
Applicant: Philip E. Thorpe , Steven W. King , Boning Gao
Inventor： Philip E. Thorpe , Steven W. King , Boning Gao
IPC: A61K39/00 , A61K39/40 , A61K39/395 , A01N25/00 , C07K1/00
CPC classification number: A61K47/6813 , A61K47/6435 , Y10S514/834 , Y10S530/827 , Y10S530/829
Abstract: The invention embodies the surprising discovery that Tissue Factor (TF) compositions and variants thereof specifically localize to the blood vessels within a vascularized tumor following systemic administration. The invention therefore provides methods and compositions comprising coagulant-deficient Tissue Factor for use in effecting specific coagulation and for use in tumor treatment. The TF compositions and methods of present invention may be used alone, as TF conjugates with improved half-life, or in combination with other agents, such as conventional chemotherapeutic drugs, targeted immunotoxins, targeted coaguligands, and/or in combination with Factor VIIa (FVIIa) or FVIIa activators.
-
公开(公告)号：US07041635B2
公开(公告)日：2006-05-09
申请号：US10353753
申请日：2003-01-28
Applicant: Hun-Taek Kim , In-Young Song , Jae Won Choi , Jin-Wook Jang , Yong-Kook Kim , Ho Soon Lee , Yung-Jue Bang , Dae-Kee Kim
Inventor： Hun-Taek Kim , In-Young Song , Jae Won Choi , Jin-Wook Jang , Yong-Kook Kim , Ho Soon Lee , Yung-Jue Bang , Dae-Kee Kim
CPC classification number: C07K14/755 , A61K48/00 , Y10S514/802 , Y10S514/834 , Y10S930/10
Abstract: The application discloses Factor VIII polypeptides comprising internal deletions of amino acids within the area of residues 741 to 1689, wherein the thrombin cleavage sites at about 741 and about 1689 are present, and a site at about 1648 is not present, as compared to human Factor VIII.
Abstract translation: 该应用公开了包含在残基741至1689的区域内的氨基酸的内部缺失的因子VIII多肽，其中存在约741和约1689的凝血酶切割位点，并且与人因子相比不存在约1648位点 八，
-
10.发明授权
公开(公告)号：US07033994B2
公开(公告)日：2006-04-25
申请号：US10168727
申请日：2000-12-21
Applicant: Tatsuya Araki , Kazuhiko Tomokiyo , Yasushi Nakatomi , Kaori Teshima , Tomoko Watanabe , Tomohiro Nakagaki
Inventor： Tatsuya Araki , Kazuhiko Tomokiyo , Yasushi Nakatomi , Kaori Teshima , Tomoko Watanabe , Tomohiro Nakagaki
CPC classification number: A61K38/37 , Y10S514/802 , Y10S514/834
Abstract: The present invention provides a pharmaceutical composition for treatment and prevention of bleeding disorders caused by platelet disorders, not caused by defect in blood coagulation factors or von Willebrand Factor but caused by reduction of circulating platelet count or platelet dysfunction, said composition comprising a hemostatic effective amount of Factor VIII and/or von Willebrand Factor. Also provided is a method for treating said bleeding, comprising administering a hemostatic effective amount of Factor VIII and/or von Willebrand Factor to patients suffering from bleeding disorders caused by platelet disorders.
